Sign in

Xingjuan (Jane) Chao

Chief Executive Officer at Ceribell
Board
Since October 2015
Age
45 years
Education
Earned a B.S. in chemistry from Peking University and a Ph.D. in biophysics from Cornell University.
Tenure
Joined CBLL in October 2015 as Chief Executive Officer and was promoted to President in July 2016.

Also at Ceribell

JSM
Joseph S. Manni
Chief Revenue Officer
RW
Raymond Woo
Chief Technology Officer
SB
Scott Blumberg
Chief Financial Officer

About

Xingjuan (Jane) Chao, aged 45 as of April 11, 2025 , combines a strong scientific academic background with extensive leadership experience. She earned a B.S. in chemistry from Peking University and a Ph.D. in biophysics from Cornell University, establishing the foundation for a career that spans both research and executive management.

Before joining CBLL, she garnered significant experience through roles at prominent organizations, including serving as a management consultant at McKinsey & Company (July 2007–January 2013), as Senior Strategy Manager at Novartis AG (January 2013–June 2014), and as Principal Manager of Portfolio Management Strategy at Genentech, Inc. (June 2014–August 2015).

Since joining CBLL as Chief Executive Officer in October 2015 and later being promoted to President in July 2016, her leadership has been pivotal in steering the company’s strategic direction. Her contributions extend to board memberships and key industry agreements, underscoring a well-rounded professional profile that supports both operational and strategic growth.

$CBLL Performance Under Xingjuan (Jane) Chao

Past Roles

OrganizationRoleDate RangeDetails
Magnus Medical, Inc. Board of Directors Nov 2021 - Feb 2025 External board position
CeriBell, Inc. President July 2016 - (pre-CEO transition) Held prior to promotion to CEO
Genentech, Inc. Principal Manager of Portfolio Management Strategy Jun 2014 - Aug 2015 N/A
Novartis AG Senior Strategy Manager Jan 2013 - Jun 2014 N/A
McKinsey & Company Management Consultant Jul 2007 - Jan 2013 N/A

Fixed Compensation

Data from  FY 2024
Component NameAmountPayment ScheduleAdditional Details
Base Salary$501,000 Annually (effective April 1, 2024) Annual salary for 2024
Car Travel Reimbursements$32,741 As incurred for travel commute Included under "All Other Compensation"

Performance Compensation

Data from  FY 2024

Annual Cash Bonus

MetricValueDetails
Bonus Target$250,500 50% of base salary for 2024
Actual Bonus$278,055 Paid in early 2025 upon achievement of pre-established company performance objectives
Performance Weight100% Tied exclusively to corporate performance objectives

Stock Option Awards

MetricValueDetails
Grant DateApril 23, 2024 -
Shares Awarded166,536 shares Total number of securities underlying the options
Exercise Price$9.406 per share -
Vesting ScheduleMonthly over 24 months Beginning May 1, 2024; 1/24th of total shares vest each month, subject to continued service
Grant-date Fair Value$1,013,233 As disclosed in the Summary Compensation Table
Performance MetricsN/ANo performance metrics, targets, or thresholds are disclosed for the stock option awards